Victoria Johnson

Molybdenum’s antioxidative properties may help reduce systemic inflammation, ROS, and uric acid levels.

Productivity improved in patients with IA after starting treatment.

Other recent research found that having osteoarthritis increased the risk of developing carpal tunnel syndrome.

Rates of adverse events leading to discontinuation were similar between populations of moderate-to-severe psoriasis and psoriatic arthritis.

Higher risk associations also included being a current smoker and socioeconomic deprivation.

Another recent study found that the risk of joint damage and gout flares were most important to patients when considering ULT discontinuation.

More patients also switched from combination therapy to monotherapy at any time in both analyzed database populations.

Around 20% of participants had ultrasound evidence of at least 1 active enthesitis, and 15.7% had ultrasound signs of at least 1 active synovitis at examination.

Each unit increase in TyG index was associated with 40% higher odds of gout.

Adoption rates of infliximab biosimilars only sped up after introduction of a third biosimilar.

A separate paper also found that the overall risk of serious infection was low in new users of targeted therapy.

Both treatment arms experienced significant improvements in measured parameters from baseline, although these were not all statistically significant.

A retrospective analysis compared data from the BE OPTIMAL and BE COMPLETE trials with data from pivotal trials of the IL-23–targeting therapies.

The study was not adequately powered to assess a significant association with cancer mortalities.

Adalimumab-aaty was FDA approved on May 23, 2023, and became commercially available in the US on July 2, 2023.

Similar trends were seen in study participants that transitioned from receiving placebo to bimekizumab after study week 16.

Adjusted analyses reveal a statistically significantly higher prescription medication cost in patients with RA compared to those without.

For This Year in Medicine, CGTLive looks back at a landmark first approval, the new treatment opportunities it has provided, and the unmet needs in the field it has brought to light.

With several newly approved therapies hitting the market and an overflowing pipeline, the FDA has stepped in to help keep the burgeoning world of biotech on track.

The BLA was supported by positive data from 54 patients with hemophilia B in the pivotal phase 3 HOPE-B trial.

“The approval of ZYNTEGLO marks a watershed moment for the field of gene therapy," Andrew Obenshain, CEO of Bluebird Bio says.

Clinical and industry leaders share their perspectives on the importance of collaboration in developing treatments for rare diseases.

A multitude of promising new investigative therapies are on the horizon for inherited retinal disease.

Exciting new therapies for sickle cell disease are on the horizon. We explored some of the most promising investigational therapies in recognition of National Blood Donor Month.

The study presented at the 2021 AAN Meeting follows the complete response letter issued by the FDA to Acadia Pharmaceuticals due to deficiencies in their sNDA.

Researchers examine how biomarkers are differentially mapped to MRI measures of cortical thickness.

Increasing OSA severity was associated with increasing markers of obesity.

Alector’s announcement about the INVOKE-2 study follows a similar update regarding its INFRONT-3 study for frontotemporal dementia.

Obese individuals were found to have a higher odds ratio of developing IIH compared to non-obese people.